Effects	effects	O	O
of	of	O	O
the	the	O	O
novel	novel	O	O
compound	compound	B_chemical	O
aniracetam	aniracetam	S_chemical	O
(	(	O	O
Ro	ro	O	O
13	13	O	O
-	-	O	O
5057	5057	O	O
)	)	O	O
upon	upon	O	O
impaired	impaired	O	O
learning	learning	O	O
and	and	O	O
memory	memory	O	O
in	in	O	O
rodents	rodents	O	O
.	.	O	O

The	the	O	O
effect	effect	O	O
of	of	O	O
aniracetam	aniracetam	S_chemical	O
(	(	O	O
Ro	ro	O	O
13	13	O	O
-	-	O	O
5057	5057	O	O
,	,	O	O
1-anisoyl-2-pyrrolidinone	1-anisoyl-2-pyrrolidinone	S_chemical	O
)	)	O	O
was	was	O	O
studied	studied	O	O
on	on	O	O
various	various	O	O
forms	forms	O	O
of	of	O	O
experimentally	experimentally	O	O
impaired	impaired	O	O
cognitive	cognitive	O	B_disease
functions	functions	O	I_disease
(	(	O	O
learning	learning	O	O
and	and	O	O
memory	memory	O	O
)	)	O	O
in	in	O	O
rodents	rodents	O	O
and	and	O	O
produced	produced	O	O
the	the	O	O
following	following	O	O
effects	effects	O	O
:	:	O	O
(	(	O	O
1	1	O	O
)	)	O	O
almost	almost	O	O
complete	complete	O	O
prevention	prevention	O	O
of	of	O	O
the	the	O	O
incapacity	incapacity	O	O
to	to	O	O
learn	learn	O	O
a	a	O	O
discrete	discrete	O	O
escape	escape	O	O
response	response	O	O
in	in	O	O
rats	rats	O	O
exposed	exposed	O	O
to	to	O	O
sublethal	sublethal	S_chemical	O
hypercapnia	hypercapnia	O	O
immediately	immediately	O	O
before	before	O	O
the	the	O	O
acquisition	acquisition	O	O
session	session	O	O
;	;	O	O
(	(	O	O
2	2	O	O
)	)	O	O
partial	partial	O	O
(	(	O	O
rats	rats	O	O
)	)	O	O
or	or	O	O
complete	complete	O	O
(	(	O	O
mice	mice	O	O
)	)	O	O
prevention	prevention	O	O
of	of	O	O
the	the	O	O
scopolamine-induced	scopolamine-induced	O	O
short-term	short-term	O	O
amnesia	amnesia	O	S_disease
for	for	O	O
a	a	O	O
passive	passive	O	O
avoidance	avoidance	O	O
task	task	O	O
;	;	O	O
(	(	O	O
3	3	O	O
)	)	O	O
complete	complete	O	O
protection	protection	O	O
against	against	O	O
amnesia	amnesia	O	S_disease
for	for	O	O
a	a	O	O
passive	passive	O	O
avoidance	avoidance	O	O
task	task	O	O
in	in	O	O
rats	rats	O	O
submitted	submitted	O	O
to	to	O	O
electroconvulsive	electroconvulsive	O	O
shock	shock	O	S_disease
immediately	immediately	O	O
after	after	O	O
avoidance	avoidance	O	O
acquisition	acquisition	O	O
;	;	O	O
(	(	O	O
4	4	O	O
)	)	O	O
prevention	prevention	O	O
of	of	O	O
the	the	O	O
long-term	long-term	O	O
retention-	retention-	O	O
or	or	O	O
retrieval-deficit	retrieval-deficit	O	O
for	for	O	O
a	a	O	O
passive	passive	O	O
avoidance	avoidance	O	O
task	task	O	O
induced	induced	O	O
in	in	O	O
rats	rats	O	O
and	and	O	O
mice	mice	O	O
by	by	O	O
chloramphenicol	chloramphenicol	O	O
or	or	O	O
cycloheximide	cycloheximide	S_chemical	O
administered	administered	O	O
immediately	immediately	O	O
after	after	O	O
acquisition	acquisition	O	O
;	;	O	O
(	(	O	O
5	5	O	O
)	)	O	O
reversal	reversal	O	O
,	,	O	O
when	when	O	O
administered	administered	O	O
as	as	O	O
late	late	O	O
as	as	O	O
1	1	O	O
h	h	S_chemical	O
before	before	O	O
the	the	O	O
retention	retention	O	O
test	test	O	O
,	,	O	O
of	of	O	O
the	the	O	O
deficit	deficit	O	O
in	in	O	O
retention	retention	O	O
or	or	O	O
retrieval	retrieval	O	O
of	of	O	O
a	a	O	O
passive	passive	O	O
avoidance	avoidance	O	O
task	task	O	O
induced	induced	O	O
by	by	O	O
cycloheximide	cycloheximide	S_chemical	O
injected	injected	O	O
2	2	O	O
days	days	O	O
previously	previously	O	O
;	;	O	O
(	(	O	O
6	6	O	O
)	)	O	O
prevention	prevention	O	O
of	of	O	O
the	the	O	O
deficit	deficit	O	O
in	in	O	O
the	the	O	O
retrieval	retrieval	O	O
of	of	O	O
an	an	O	O
active	active	O	O
avoidance	avoidance	O	O
task	task	O	O
induced	induced	O	O
in	in	O	O
mice	mice	O	O
by	by	O	O
subconvulsant	subconvulsant	O	O
electroshock	electroshock	O	O
or	or	O	O
hypercapnia	hypercapnia	O	O
applied	applied	O	O
immediately	immediately	O	O
before	before	O	O
retrieval	retrieval	O	O
testing	testing	O	O
(	(	O	O
24	24	O	O
h	h	S_chemical	O
after	after	O	O
acquisition	acquisition	O	O
)	)	O	O
.	.	O	O

These	these	O	O
improvements	improvements	O	O
or	or	O	O
normalizations	normalizations	O	O
of	of	O	O
impaired	impaired	O	O
cognitive	cognitive	O	B_disease
functions	functions	O	I_disease
were	were	O	O
seen	seen	O	O
at	at	O	O
oral	oral	B_chemical	O
aniracetam	aniracetam	S_chemical	O
doses	doses	O	O
of	of	O	O
10	10	O	O
-	-	O	O
100	100	O	O
mg/kg	mg/kg	O	O
.	.	O	O

Generally	generally	O	O
,	,	O	O
the	the	O	O
dose-response	dose-response	O	O
curves	curves	O	O
were	were	O	O
bell-shaped	bell-shaped	O	O
.	.	O	O

The	the	O	O
mechanisms	mechanisms	O	O
underlying	underlying	O	O
the	the	O	O
activity	activity	O	O
of	of	O	O
aniracetam	aniracetam	S_chemical	O
and	and	O	O
its	its	O	O
'	'	O	O
therapeutic	therapeutic	O	O
window	window	O	O
'	'	O	O
are	are	O	O
unknown	unknown	O	O
.	.	O	O

Piracetam	piracetam	S_chemical	O
,	,	O	O
another	another	O	O
pyrrolidinone	pyrrolidinone	O	O
derivative	derivative	O	O
was	was	O	O
used	used	O	O
for	for	O	O
comparison	comparison	O	O
.	.	O	O

It	it	O	O
was	was	O	O
active	active	O	O
only	only	O	O
in	in	O	O
six	six	O	O
of	of	O	O
nine	nine	O	O
tests	tests	O	O
and	and	O	O
had	had	O	O
about	about	O	O
one-tenth	one-tenth	O	O
the	the	O	O
potency	potency	O	O
of	of	O	O
aniracetam	aniracetam	S_chemical	O
.	.	O	O

The	the	O	O
results	results	O	O
indicate	indicate	O	O
that	that	O	O
aniracetam	aniracetam	S_chemical	O
improves	improves	O	O
cognitive	cognitive	O	B_disease
functions	functions	O	I_disease
which	which	O	O
are	are	O	O
impaired	impaired	O	O
by	by	O	O
different	different	O	O
procedure	procedure	O	O
and	and	O	O
in	in	O	O
different	different	O	O
phases	phases	O	O
of	of	O	O
the	the	O	O
learning	learning	O	O
and	and	O	O
memory	memory	O	O
process	process	O	O
.	.	O	O

